Reduced susceptibility of recombinant polyclonal antibodies to inhibitory anti-variable domain antibody responses.
The immunogenicity of therapeutic Abs is a concern as anti-drug Abs may impact negatively on the pharmacodynamics and safety profile of Ab drugs. The factors governing induction of anti-drug Abs are not fully understood. In this study, we describe a model based on mouse-human chimeric Abs for the study of Ab immunogenicity in vivo. Six chimeric Abs containing human V regions and mouse C regions were generated from six human anti-Rhesus D Abs and the Ag-binding characteristics of the parental human Abs were retained. Analysis of the immune response toward the individual chimeric Abs revealed the induction of anti-variable domain Abs including anti-idiotypic Abs against some of these, thereby demonstrating the applicability of the model for studying anti-drug Ab responses in vivo. Immunization of BALB/c, C57, and outbred NMRI mice with a polyclonal composition consisting of all six chimeric Abs demonstrated that the immunogenicity of the individual Abs was haplotype dependent. Chimeric Abs, which were nonimmunogenic when administered individually, did not become immunogenic as part of the polyclonal composition, implying the absence of epitope spreading. Ex vivo Ab-binding studies established a clear correlation between the level of immunogenicity of the Abs comprised in the composition and the impact on the pharmacology of the Abs. These analyses demonstrate that under these conditions this polyclonal Ab composition was generally less susceptible to blocking Abs than the respective mAbs.
Klitgaard
Josephine L
JL
Symphogen, Lyngby, Denmark.
Coljee
Vincent W
VW
Andersen
Peter S
PS
Rasmussen
Lone K
LK
Nielsen
Lars S
LS
Haurum
John S
JS
Bregenholt
Søren
S
D000595:Amino Acid Sequence; D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000096:biosynthesis / Q000378:metabolism*; D019138:Antibodies, Blocking / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000378:metabolism; D001666:Binding Sites, Antibody / Q000235:genetics; D005260:Female; D006801:Humans; D007106:Immune Sera / Q000378:metabolism; D007074:Immunoglobulin G / Q000378:metabolism; D007135:Immunoglobulin Variable Region / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D017434:Protein Structure, Tertiary / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000276:immunology* / Q000378:metabolism*; D012204:Rh-Hr Blood-Group System / Q000276:immunology
D000888:Antibodies, Anti-Idiotypic; D019138:Antibodies, Blocking; D000911:Antibodies, Monoclonal; D007106:Immune Sera; D007074:Immunoglobulin G; D007135:Immunoglobulin Variable Region; D011993:Recombinant Fusion Proteins; D012204:Rh-Hr Blood-Group System; C026410:Rho(D) antigen